PUBLISHER: Grand View Research | PRODUCT CODE: 1321372
PUBLISHER: Grand View Research | PRODUCT CODE: 1321372
The India ophthalmic clinical trials market size is expected to reach USD 61.01 million by 2030, growing at a CAGR of 6.58% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing prevalence of eye disorders, favorable regulatory environment, increasing investments in healthcare infrastructure, and availability of skilled workforce.
An increase in technological advancements and investment of multinational companies in the country serve as ideal opportunities for the growth of the market. Telemedicine technologies have enabled remote consultations and monitoring of patients participating in clinical trials. Remote monitoring devices such as smartphones, wearable sensors, and home monitoring systems allow researchers to collect real-time data on patients' eye health and treatment outcomes. These advancements have improved patient recruitment & retention and have reduced the burden of frequent clinic visits.
Furthermore, the increasing prevalence of eye conditions such as macular degeneration, diabetic retinopathy, and glaucoma are key drivers for the ophthalmic clinical trials industry's growth. As the population ages in the country and the incidence of these conditions rises, there is a growing demand for effective treatments and therapies. Furthermore, advancements in genetic research and personalized medicine are expected to drive innovation in this field, leading to more specialized and efficient treatments for eye diseases. These factors collectively contribute to the market growth in the coming years.